NAC
N-Acetyl Cysteine
Key Benefits
Glutathione Production
Boosts glutathione levels, enhancing antioxidant defense and detoxification capacity.
Liver Support
Protects liver function and supports Phase II detoxification pathways.
Respiratory Health
Breaks down mucus and supports lung function, used clinically for respiratory conditions.
Mental Health
May reduce obsessive-compulsive and addictive behaviors through glutamate modulation.
Activation Synergies
Vitamin C works synergistically with NAC to support glutathione production and enhance overall antioxidant defense.
Selenium is required for glutathione peroxidase activity. Together with NAC, they create a powerful glutathione-based antioxidant system.
Glycine is another precursor to glutathione. Combined with NAC, they ensure optimal glutathione synthesis.
Recommended Dosage
medical_servicesTake on empty stomach for best absorption. May cause sulfur-like odor. Start with lower doses to assess tolerance. Effects build over weeks.
Deficiency Indicators
- Chronic oxidative stress
- Liver issues or exposure to toxins
- Respiratory congestion
- Low glutathione levels
Scientific Citations
N-Acetylcysteine: Research Summary
Research & Sources
What the evidence says — with links to the original studies
N-acetylcysteine (NAC) is a cysteine derivative and glutathione precursor with a strong, established evidence base in two clinical domains and a growing but mixed body of evidence in a third. As a glutathione replenisher it is the first-line, life-saving antidote for acetaminophen (paracetamol) overdose, dramatically reducing hepatotoxicity when given early (within 8-10 hours of ingestion). As a mucolytic/antioxidant it has a Cochrane-supported role in chronic bronchitis/COPD, where pooled data show a modest reduction in exacerbations, though the benefit is driven partly by older trials and a large 2023 meta-analysis found no significant effect on exacerbations or lung function. In psychiatry, NAC has been studied as an adjunct across OCD and related disorders (trichotillomania, skin-picking), substance-use craving, schizophrenia, and mood disorders; the evidence is emerging and inconsistent, with the strongest signals for schizophrenia adjunct and substance craving, and mixed/underpowered results for OCD and mood disorders. NAC is generally safe and well tolerated. Its US regulatory status is contested: because NAC was approved as a drug (1963) before being marketed as a supplement, the FDA has stated it is technically excluded from the dietary-supplement definition, and since 2022 permits sales only under enforcement discretion.
Supporting Evidence
Mucolytics (including NAC) reduce exacerbations vs placebo; about 8 people need treatment for 9 months for one extra person to avoid a flare-up, with slightly fewer disability days. Moderate certainty; benefit larger in older (1970s-90s) trials.
Confirms NAC as glutathione precursor and antidote that neutralizes the toxic metabolite NAPQI. Severe hepatotoxicity in only ~6.1% when treated within 10 hours vs ~41% when delayed beyond 16 hours; near-universal recovery with early treatment.
Six RCTs, 195 patients. NAC added to SSRIs may benefit patients with moderate-to-severe OCD over 5-8 weeks; benefit not significant for very short or >12-week durations. Calls for larger multi-center trials.
Strongest evidence for schizophrenia adjunct; moderate evidence for substance (cocaine/cannabis) craving reduction; OCD and mood disorders mixed/inconsistent. NAC safe and well tolerated at ~2000-2400 mg/day. Open-access full text also at moodclinic.ca.
9 RCTs, 2,137 patients (doses 600 mg/day to 1,800 mg twice daily). Included here for completeness of the respiratory evidence, though its primary result was null (see opposing sources).
Opposing / Critical Views
Across 6 exacerbation studies (1,944 patients) NAC did NOT reduce acute exacerbations (OR 1.12, 95% CI 0.92-1.36, p=0.26) and showed no significant effect on FEV, vital capacity, quality of life, or glutathione. Contrasts with the Cochrane review's modest positive finding, underscoring a mixed respiratory picture.
Placebo-controlled add-on RCT in children/adolescents; NAC did not separate from placebo for pediatric hair-pulling, contrasting with an earlier positive adult trichotillomania RCT (Grant et al. 2009). Illustrates the inconsistent, population-dependent psychiatric evidence.
Full-text & official documents
- download Poole et al. — Cochrane Review: Mucolytic agents for chronic bronchitis or COPD (CD001287.pub6, 2019)
- download Ooi et al. — N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence (BioMed Research International, 2018)
- download FDA — Final Guidance: Enforcement Discretion for Certain NAC Products (regulatory status, 2022)
Educational summary of published research — not medical advice. Consult a qualified professional before supplementing.
Have You Tried This?
Join our collective laboratory. Share your experience level with this topic and help others gauge the journey.
Based on .
No one has shared yet. Be the first to place a pin on the map.
check_circle You marked yourself as .
Status: In Your Stack Status: Not in Stack